Pages that link to "Q28361577"
Jump to navigation
Jump to search
The following pages link to Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro (Q28361577):
Displaying 50 items.
- Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors (Q24645702) (← links)
- Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of Valopicitabine (Q27477522) (← links)
- Therapeutic issues in HIV/HCV-coinfected patients (Q27481053) (← links)
- Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons (Q28274676) (← links)
- (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro (Q28316326) (← links)
- Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells (Q28323830) (← links)
- Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro (Q28326720) (← links)
- Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro (Q28327295) (← links)
- Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds (Q28328538) (← links)
- Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro (Q28333682) (← links)
- Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1 (Q28335917) (← links)
- Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1 (Q28339702) (← links)
- Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet (Q28341972) (← links)
- Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs (Q28343742) (← links)
- Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor (Q28367556) (← links)
- The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo (Q28379426) (← links)
- Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides (Q28379530) (← links)
- Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors (Q34047338) (← links)
- Exploiting drug repositioning for discovery of a novel HIV combination therapy (Q34124794) (← links)
- Treatment of hepatitis C virus and HIV co-infections (Q34422699) (← links)
- Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients (Q34631679) (← links)
- Hepatitis C in the HIV-infected patient (Q35105717) (← links)
- Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS) (Q35156244) (← links)
- Development of Inhibitors of Reverse Transcriptase and Protease as Therapeutics Against HIV Infection (Q35174341) (← links)
- Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy (Q35232016) (← links)
- Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition (Q35325810) (← links)
- Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report (Q35362117) (← links)
- Antiviral therapy for human immunodeficiency virus infections (Q35366050) (← links)
- Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection (Q35810419) (← links)
- Hepatitis C-HIV coinfection: current and future therapy (Q35917242) (← links)
- Antiviral therapy: current concepts and practices (Q36070394) (← links)
- Therapy of hepatitis C in patients with HIV infection (Q36162359) (← links)
- Therapy insight: Management of hepatitis C in patients coinfected with HIV. (Q36304129) (← links)
- Mechanisms of action of ribavirin against distinct viruses (Q36312805) (← links)
- Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients (Q37142229) (← links)
- 3'-Azido-3'-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation (Q37191116) (← links)
- Clinical applications of 3'-azido-2',3'-dideoxythymidine (AZT) and related dideoxynucleosides (Q37995597) (← links)
- Antiviral therapy in human immunodeficiency virus infection (Q38709585) (← links)
- Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination (Q38848491) (← links)
- Drug interactions with zidovudine phosphorylation in vitro. (Q39779916) (← links)
- Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro (Q39784283) (← links)
- Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes (Q39785307) (← links)
- Substituted imidazopyridines as potent inhibitors of HCV replication (Q39869987) (← links)
- Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase (Q39902300) (← links)
- In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. (Q40291210) (← links)
- Zalcitabine. Clinical pharmacokinetics and efficacy. (Q40447103) (← links)
- Characteristics of hepatitis C virus infection in HIV-infected people (Q40663778) (← links)
- The anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. (Q40820971) (← links)
- Comparative pharmacokinetics of antiviral nucleoside analogues (Q40886850) (← links)
- Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection (Q41494492) (← links)